Combination of Chemotherapy and Hormones in Prostatic Cancer

  • J. D. Schmidt
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)


The National Prostatic Cancer Project in a four-year period has accessioned 301 patients with newly diagnosed Stage D-2 prostatic cancer into a treatment protocol comparing cyclophosphamide (Cytoxan) plus estramustine phosphate (Estracyt) versus Cytoxan plus diethylstilbestrol (DES) versus either DES or bilateral orchiectomy. The three treatment arms appear comparable in terms of entry criteria with the exception of elevated acid phosphatase for one arm which as yet has not influenced the response rates. Thus far, toxicities to the chemotherapy combination treatment arms have not been excessive although more prevalent than in the DES/orchi-ectomy arm. Major toxicities have been anemia, leukopenia and nausea and vomiting. Preliminary data show that the treatment arm consisting of DES plus Cytoxan is showing a slight but nonsignificant advantage in delaying progression of the disease compared to the other two treatment arms at the initial 12-week evaluation. Patient follow-up and data collection is still not complete for the assessment of survival and response durations. Approximately one-third of patients entered into the study are still on original or crossover therapy with 75% of patients still in that category. More complete and meaningful data should be available in another 18 months.


Endocrine Therapy Estramustine Phosphate Soft Tissue Metastasis Bilateral Orchiectomy Divided Daily Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J.D. Schmidt, W.W. Scott, R. Gibbons, D.E. Johnson, G.R. Prout, S. Loening, M. Soloway, J. deKernion, J.E. Pontes, N.H. Slack and G.P. Murphy, Chemotherapy programs of the National Prostatic Cancer Project (NPCP), Cancer 45:1937 (1980).PubMedGoogle Scholar
  2. 2.
    C. Huggins and C.V. Hodges, Studies on prostatic cancer: Effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res. 1:293 (1941).Google Scholar
  3. 3.
    P.C. Walsh, Physiologic basis for hormonal therapy in carcinoma of the prostate, Urol. Clin. North Am. 2:125 (1975).PubMedGoogle Scholar
  4. 4.
    C.E. Blackard, D.P. Byar and W.P. Jordan, Orchiectomy for advanced prostatic carcinoma — a re-evaluation, Urology 1:553 (1973).PubMedCrossRefGoogle Scholar
  5. 5.
    J.D. Schmidt, Chemotherapy of prostatic cancer, Urol. Clin. North Am. 2:185 (1975).PubMedGoogle Scholar
  6. 6.
    J.D. Schmidt, Developments in the endocrine therapy of prostatic cancer, Reviews on Endocrine-Related Cancer 5:13 (1980).Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • J. D. Schmidt
    • 1
  1. 1.University of California Medical CenterSan DiegoUSA

Personalised recommendations